Moreau, C, Delval, A, Tiffreau, V, Defebvre, L, Dujardin, K, Duhamel, A, Petyt, G, Hossein-Foucher, C, Blum, D, Sablonnière, B, Schraen, S, Allorge, D, Destée, A, Bordat, R, Devos, D. Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013; 84(5): 552–555.CrossRefGoogle ScholarPubMed

Ondo, WG, Shinawi, L, Davidson, A, D Lai, . Memantine for non-motor features of Parkinson’s disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011; 17(3): 156–159.CrossRefGoogle ScholarPubMed

Wang, HF, Yu, JT, Tang, SW, Jiang, T, Tan, CC, Meng, XF, Wang, C, Tan, MS, Tan, L. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86(2): 135–143.CrossRefGoogle ScholarPubMed

Aarsland, D, Ballard, C, Walker, Z, Bostrom, F, Alves, G, Kossakowski, K, Leroi, I, Pozo-Rodriguez, F, Minthon, L, Londos, E. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8(7): 613–618.CrossRefGoogle Scholar

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 19 July 2022 via www.medicinescomplete.com.Google Scholar

Emre, M, Tsolaki, M, Bonuccelli, U, Destée, A, Tolosa, E, Kutzelnigg, A, Ceballos-Baumann, A, Zdravkovic, S, Bladström, A, Jones, R ; 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9(10): 969–977.CrossRefGoogle ScholarPubMed

Gomolin, IH, Smith, C, Jeitner, TM. Once-daily memantine: pharmacokinetic and clinical considerations. J Am Geriatr Soc 2010; 58(9): 1812–1813. https://cdpc.sydney.edu.au/wp-content/uploads/2019/06/deprescribing-guideline.pdf.CrossRefGoogle ScholarPubMed

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 19 July 2022 via www.medicinescomplete.com.Google Scholar

Kavirajan, H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf 2009; 8(1): 89–109.CrossRefGoogle ScholarPubMed

Kawashima, S, Matsukawa, N. Memantine for the patients with mild cognitive impairment in Parkinson’s disease: a pharmacological fMRI study. BMC Neurol 2022; 22(1): 175.CrossRefGoogle Scholar

Kuns, B, Rosani, A, Varghese, V. Memantine. [Updated 2022 May 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: www.ncbi.nlm.nih.gov/books/NBK500025/Google Scholar

Leroi, I, Overshott, R, Byrne, EJ, Daniel, E, Burns, A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 2009; 24(8): 1217–1221.CrossRefGoogle ScholarPubMed

Mirabegron. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 19 July 2022 via www.medicinescomplete.com.Google Scholar

Mirabegron. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 10 March 2023 via www.micromedexsolutions.com.Google Scholar

Rogawski, MA, Wenk, GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9(3): 275–308.CrossRefGoogle ScholarPubMed

Summary of Product Characteristics – Ebixa 10 mg film-coated tablets. Lundbeck Limited. Electronic Medicines Compendium: Ebixa 10 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 19 July 2022 via www.medicines.org.uk.Google Scholar

Varanese, S, Howard, J, Di Rocco, A. NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson’s disease. Mov Disord 2010; 25(4):508–510.CrossRefGoogle ScholarPubMed

Vidal, EI, Fukushima, FB, Valle, AP, Villas Boas, PJF. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementia. J Am Geriatr Soc 2013; 61(1): 170–172.CrossRefGoogle ScholarPubMed

Wesnes, KA, Aarsland, D, Ballard, C, Londos, E. Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015; 30(1): 46–54.CrossRefGoogle ScholarPubMed